Immediate Impact
65 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
2024 Standout
Works of Dean Ruether being referenced
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
2020 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Dean Ruether | 238 | 257 | 102 | 203 | 39 | 690 | |
| Michael Pohl | 259 | 285 | 40 | 157 | 47 | 755 | |
| Christoph Schukro | 203 | 223 | 95 | 139 | 41 | 816 | |
| Jorge Arellano | 205 | 343 | 89 | 266 | 40 | 840 | |
| Edward C. Saltzstein | 160 | 218 | 69 | 329 | 50 | 848 | |
| San‐Chi Chen | 166 | 250 | 32 | 115 | 51 | 746 | |
| F. Valduga | 311 | 252 | 62 | 179 | 25 | 665 | |
| Fang Cheng | 157 | 176 | 40 | 236 | 57 | 746 | |
| L.V.A.M. Beex | 166 | 540 | 150 | 115 | 32 | 794 | |
| Tian Tian | 228 | 264 | 58 | 80 | 67 | 836 | |
| Kenneth Wong | 164 | 111 | 110 | 120 | 52 | 793 |
All Works
Login with ORCID to disown or claim papers
Loading papers...